# CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy

> **NCT05215470** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Hospital das Clínicas de Ribeirão Preto** · enrollment: 100 (estimated)

## Conditions studied

- Renal Cancer Metastatic

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT05215470
- **Lead sponsor:** Hospital das Clínicas de Ribeirão Preto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-01-18
- **Primary completion:** 2024-11-30
- **Final completion:** 2026-11-30
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2024-07-03

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05215470

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05215470, "CLARA: Somatic and Germline Mechanisms That Impact Renal Cancer Immunotherapy". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05215470. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*